Humanized Mouse and Rat Model Market

Humanized Mouse and Rat Model Market by Type (Genetic, Cell-Based (CD34, PBMC, BLT)), Application (Neuroscience, Hematopoesis, Oncology, Immunology & Infectious Diseases) & End User (Pharmaceutical & Biotechnology Companies, CRO)) - Global Forecast to 2022

Report Code: BT 4938 Mar, 2018, by marketsandmarkets.com

[189 Pages Report] MarketsandMarkets forecasts the humanized mouse models’ market to grow from USD USD 73.9 million in 2016 to USD 128.9 million by 2022, at a compounded annual growth rate (CAGR) of 9.9% during the forecast period. Moreover, the humanized rat models’ market is expected to reach USD 8.9 million by 2022 from USD 5.6 million in 2016, at a CAGR of 8.4% during the forecast period. The key factors propelling the growth of the market are the increasing number of research activities involving humanized models, growing demand for personalized medicine, increasing number of R&D activities in pharmaceutical and biotechnology companies, and continuous support in the form of investments and grants from the government and private sectors. The objective of the report is to define, describe, and forecast the humanized mouse and rat model market size based on type, application, end user and region.      

Humanized Mouse and Rat Model Market

Humanized Mouse and Rat Model Market

By type, the humanized mouse model segment to account for the largest share of the humanized mouse and rat model market in 2017

Based on type, the market is segmented into humanized mouse and humanized rat. The Humanized mouse market is further segmented into cell-based and genetic based humanized mouse model. The genetic humanized mouse models segment accounted for the largest share of the market. The large share of this segment can be attributed to the wide use of genetic humanized mouse models in the analysis of compounds, biological efficacy and safety testing, study of drug metabolism and disposition, and investigation of immune system development and function.

By Application, the oncology segment to account for the largest share of the humanized mouse model market in 2017

Based on application, the market is segmented into oncology, immunology and infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications. The oncology segment is expected to witness the highest growth, owing to the rising number of cancer research activities and increasing innovation to develop humanized mouse models tailored to meet the specific needs of cancer research.

By end user, the CROs segment to witness the highest growth during the forecast period (2017-2022)

Based on end user, the market is segmented into pharmaceutical & biotechnology companies, contract research organizations (CROs), and academic & research institutions. The CROs segment is estimated to register the highest CAGR during the forecast period due to the growth in the number of pharmaceutical companies outsourcing their preclinical studies to CROs.

Humanized Mouse and Rat Model Market

North America to account for the largest market size in 2017

The North American region is leading the humanized mouse models’ market is expected to account for the largest share of the market in 2017. Growth in this regional segment can primarily be attributed to growing biomedical research, preclinical activities by CROs and pharmaceutical R&D, continued and responsible use of animals ensured by animal care organizations, increasing monoclonal antibody production in the US along with growing stem cell research, and government support for the development of protein drugs in Canada

Asia Pacific market is projected to grow at the highest CAGR during the forecast period, owing to international alliances for R&D activities in China, initiatives to reduce approval time for drugs, mandatory animal testing for all pharmaceutical drugs and cosmetics in China, increasing investments from the government and private sectors in China’s life sciences sector, growing biomedical and medical research, and research in regenerative medicine in Japan. Furthermore, the growth of the biomedical industry in India, development of bio-clusters to boost India’s biotechnology, growth in translational and biomedical research in Singapore, increase in animal research in Malaysia, and ongoing biomedical research activities in Australia are also driving the growth of the market in Asia Pacific.

Market Dynamics

Driver: Growing demand for personalized medicine

Personalized medicine is the process of developing tailored medicines to target individualized treatment and care based on personal and genetic variations. These medicines are designed through the use of animal models, particularly mice models. Immune-deficient models are transplanted with human tissues and the disease expressed is recorded. This is followed by treating the model with a whole series of drugs or gene therapies to find the most suitable treatment, thus generating suitable or personalized medicine for patients.

Currently, cancer is a major burden on the healthcare systems across geographies. By 2020, the direct/indirect cost of cancer is estimated to be USD 300 billion in the US. Several in vitro and in vivo strategies are being developed in an attempt to combat the rising prevalence of cancer and offer effective treatments to patients. One of the major developments in this regard is the emergence of humanized mouse and rat models as they have high predictive power for the efficacy of standard and novel anti-cancer therapeutics. Several research studies are being conducted to develop better mice models that can mimic the human genome and respond to a wide range of human diseases. Mouse avatars are one of the most significant innovations in this regard. Avatar mice are developed by implanting cancer cells in immunodeficient mice, resulting in the generation of tumors. Such mice are addressed as personalized mice models. In 2014, Champions Oncology developed mouse avatars for personalized medicine; the company engrafted patient tumors under the skin of immune-deficient mice to study cancer treatments.

Advances in genomics, proteomics, and metabolomics; the completion of the Human Genome Project; the development of targeted diagnostics and therapeutics; and the growing emphasis on health, wellness, and prevention are some of the pivotal factors stimulating the demand for personalized medicine. The growing demand for personalized medicine is in turn expected to spur the demand for humanized mouse and rat models.

Restrain: High cost of humanized models

Humanized models are created with the engraftment of human cells, genes, or tissues into an immunodeficient mouse or rat. Considering the cost of creating and maintaining these models, humanized models used in experiments can cost thousands of dollars even in the case of a single patient. Moreover, using humanized models in government-funded basic research can also be cost-prohibitive. These are the major factors limiting the wider adoption of humanized models across the globe.

Opportunity: Increased production of monoclonal antibodies

With personalized medicine gaining in importance, monoclonal antibodies (mAbs) showcase an enormous potential to treat a wide range of diseases. This is a positive indicator for market growth as mouse models are extensively used in the production of mAbs. Researchers have replaced few parts of mouse antibodies with human components; the final antibodies with a mixture of human and mouse components are known as chimeric antibodies. Some monoclonal antibodies are now entirely human as a larger portion of the human component is engrafted in the mouse antibody.

Challenge: Alternative methods of animal testing

The development of efficient and reliable alternatives to animal testing is posing major challenges to the growth of the global humanized mouse and rat models market. Increasing pressure from animal rights activists is compelling research institutes and companies to seek options to minimize the use of animals in research activities. This has further led to the development of a number of alternatives for testing, such as in vitro methods and models based on human cells and tissue cultures; computerized patient-drug databases and virtual drug trials; computer models and simulations; organs-on-chips; stem cell and genetic testing methods; and non-invasive imaging techniques, such as MRI, CT, and microdosing. These alternatives offer various benefits, resulting in their growing adoption in research activities.

Scope of the Report

Report Metric

Details

Market size available for years

2015–2022

Base year considered

2016

Forecast period

2017–2022

Forecast units

Million (USD)

Segments covered

Type (Humanised Mouse Model {Cell-Based (CD34, PBMC, BLT), Genetic Based} and Humanized Rat Model), Application (Oncology, Immunology and infectious disease, neurosciences, hematopoiesis, other applications) and End-User (Pharmaceutical & Biotechnology Companies, Contract Research Organization, Academic and Research Institutes) and Region

Geographies covered

North America, Europe, APAC, and Rest of the World

Companies covered

Charles River Laboratories, International, Inc. (U.S.), The Jackson Laboratory (U.S.), Taconic Biosciences, Inc. (U.S.), Trans Genic, Inc. (Japan), Genoway (France), Horizon Discovery Group (UK), Ingenious Targeting Laboratory (US). Crown Biosciences (US), Champions Oncology (US), HERA Biolabs (US), Vitalstar Biotechnology (China), Axenis (France), and  Harbour Antibodies (China).

The research report categorizes the mice model market to forecast the revenues and analyze the trends in each of the following sub-segments:

Humanized Mouse and Rat Model Market

By Type

  • Humanized Mouse Models
    • Genetic Humanized Mouse Models
    • Cell-based Humanized Mouse Models
      • CD34 Humanized Mouse Models
      • PBMC Humanized Mouse Models
      • BLT Humanized Mouse Models
  • Humanized Rat Models

By Application

  • Oncology
  • Immunology and Infectious Diseases
  • Neuroscience
  • Toxicology
  • Hematopoiesis
  • Other Applications

By End User

  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations
  • Academic & Research Institutions

By Region

  • North America
    • US
    • Canada
  • Europe
    • EU5
    • Rest of Europe (RoE)
  • APAC
  • Rest of the World

Key Market Players

The major market players in the humanized mouse models market include The Jackson Laboratory (US), Taconic Biosciences, Inc. (US), Horizon Discovery Group plc (UK), genOway, S.A. (France), Charles River Laboratories (US), Harbour Antibodies BV (China), Hera BioLabs (US), Vitalstar Biotechnology Co., Ltd. (China), inGenious Targeting Laboratory (US), AXENIS S.A.S (France), Crown Bioscience, Inc. (US), Transgenic, Inc. (Japan), and Champions Oncology, Inc. (US). The major players in the humanized rat models market include Horizon Discovery Group plc (UK), Hera BioLabs (US), and Yecuris Corporation (US).

Taconic is the second most leading players in the global humanized mouse and rat model market. The company is a provider of cell based and genetically modified mice models and supporting services such as custom model generation, imaging studies, and surgical services. The firm also has other distribution networks in India, Japan, and Singapore. A broad distribution network and a wide range of humanized mouse strains position the firm as one of the major players in the global cell based and genetic humanized mouse model market.

Recent Developments

  • China’s Cyagen Biosciences Inc. is selling genetically modified mice for USD 17,000 a pair.
  • In 2019, Taconic Biosciences launched TRUBIOME a genetically enginerred mice
  • ARTE10 alzheimers disease mouse model
  • In 2018, Charles River entered into a collaborative agreement with genOway inorder to access it customers with 2,000 ready-to-use knockout mouse models.
  • In 2018, Taconic Biosciences and Cyagen Biosciences entered into a strategic partnership. Under this partnership, the two companies will combine resources to provide the global scientific community with access to premium custom model design and generation services

Critical questions the report answers:

  • Where will all these developments take the industry in the long term?
  • What are the upcoming trends for the mice model market?
  • Which segment provides the most opportunity for growth?
  • Who are the leading vendors operating in this market?
  • What are the opportunities for new market entrants?

Available customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (Up to 5)

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Table of Contents

1 Introduction (Page No. - 17)
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Markets Covered
           1.3.2 Years Considered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology (Page No. - 21)
    2.1 Research Data
           2.1.1 Secondary Data
                    2.1.1.1 Key Data From Secondary Sources
           2.1.2 Primary Data
                    2.1.2.1 Key Data From Primary Sources
                    2.1.2.2 Key Industry Insights
    2.2 Market Size Estimation Methodology
    2.3 Market Breakdown and Data Triangulation
    2.4 Assumptions for the Study

3 Executive Summary (Page No. - 32)

4 Premium Insights (Page No. - 37)
    4.1 Humanized Mouse Models: Market Overview
    4.2 Humanized Rat Models: Market Overview
    4.3 Rat Model Market Share, By Region and End User (2017)
    4.4 Market, By Type, 2017 vs 2022
    4.5 Geographic Snapshot of the Market

5 Market Overview (Page No. - 41)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 Increasing Number of Research Activities Involving Humanized Models
                               5.2.1.1.1 Mouse Models for Immunodeficiency Disorders
                               5.2.1.1.2 Humanized Models for Cancer
                               5.2.1.1.3 Mouse Models for Rare Diseases and Graft-Versus-Host Disease
                    5.2.1.2 Growing Demand for Personalized Medicine
                    5.2.1.3 Continuous Support in the Form of Investments and Grants From the Government and Private Sectors
                               5.2.1.3.1 Funding/Grants By the National Institutes of Health (NIH)
                               5.2.1.3.2 Funding/Grants Received From Other Government Bodies
                    5.2.1.4 Increasing Number of R&D Activities in Pharmaceutical and Biotechnology Companies
           5.2.2 Restraints
                    5.2.2.1 High Cost of Humanized Models
                    5.2.2.2 Regulations & Laws Formulated for Ethical Use of Animals
                               5.2.2.2.1 The Animal Welfare Act (AWA)
                               5.2.2.2.2 Public Health Service (PHS) Policy on Humane Care and Use of Laboratory Animals
           5.2.3 Opportunities
                    5.2.3.1 Increased Production of Monoclonal Antibodies
                    5.2.3.2 Rising Demand for Humanized Rat Models
           5.2.4 Challenges
                    5.2.4.1 Advances in Zebrafish Model Development
                    5.2.4.2 Alternative Methods of Animal Testing
                    5.2.4.3 Limitations of Humanized Mouse Models

6 Clinical Trails & Research Studies Assessment (Page No. - 51)
    6.1 Introduction
    6.2 Clinical Trials
    6.3 Research Studies

7 Humanized Mouse and Rat Models Market, By Type (Page No. - 58)
    7.1 Introduction
    7.2 Humanized Mouse Models
           7.2.1 Genetic Humanized Mouse Models
           7.2.2 Cell-Based Humanized Mouse Models
                    7.2.2.1 CD34 Humanized Mouse Models (HU-CD34)
                    7.2.2.2 PBMC Humanized Mouse Models
                    7.2.2.3 BLT Humanized Mouse Models
    7.3 Humanized Rat Models

8 Humanized Mouse Models Market, By Application (Page No. - 71)
    8.1 Introduction
    8.2 Oncology
           8.2.1 Key Developments By Industry Players to Strengthen Cancer Research
           8.2.2 Continuous Grants/Funds to Support Cancer Research Studies
    8.3 Immunology and Infectious Diseases
           8.3.1 Grants/Funds for Immunology and Infectious Diseases Research
    8.4 Neuroscience
           8.4.1 Grants/Funds for Neurological Research
    8.5 Toxicology
    8.6 Hematopoiesis
    8.7 Other Applications
           8.7.1 Increasing Funding for Rare Diseases, Graft-Vs-Host Diseases, and Cardiovascular Disease Research

9 Humanized Mouse Models Market, By End User (Page No. - 86)
    9.1 Introduction
    9.2 Pharmaceutical & Biotechnology Companies
    9.3 Contract Research Organizations
    9.4 Academic & Research Institutions

10 Humanized Mouse Models Market, By Region (Page No. - 94)
     10.1 Introduction
     10.2 North America
             10.2.1 Us
                        10.2.1.1 Availability of Support for Research in the Us
                        10.2.1.2 Growing Focus of Oncology Research in the Us
                        10.2.1.3 Conferences and Other Events Contributing to the Spread of Innovation and Awareness
                        10.2.1.4 Growing Production of Monoclonal Antibodies
                        10.2.1.5 Development of Biosimilars Boosting the Demand for Preclinical Services
             10.2.2 Canada
                        10.2.2.1 Growing Stem Cell Research in Canada
                        10.2.2.2 Government Support for the Development of Protein Drugs
     10.3 Europe
             10.3.1 EU5
                        10.3.1.1 Germany: Flourishing Biotechnology Industry
                        10.3.1.2 UK: Emphasis on Quality Research Results and Increase in Cell Therapy Preclinical Research
                        10.3.1.3 France: Funding for Rare Disease Projects
                        10.3.1.4 Italy: Growth in the Biotechnology and Pharmaceutical Sector
                        10.3.1.5 Spain: Availability of VC Funding for Life Sciences
             10.3.2 Rest of Europe (RoE)
                        10.3.2.1 Growing Investments in Research By Sweden & Denmark
                        10.3.2.2 Focus on Rare Disease Research Projects
     10.4 Asia Pacific
             10.4.1 China: Strong Research Expenditure, Well-Structured CRO Industry
             10.4.2 Rising Focus on Personalized Medicine in China
             10.4.3 Increasing Public & Private Investments in China’s Life Sciences Sector
             10.4.4 Initiatives to Reduce Long Approval Times in China
             10.4.5 Japan: Growth in Biomedical & Medical Research
             10.4.6 Research Into Regenerative Medicine in Japan
             10.4.7 Growth of the Pharmaceutical Industry in India
             10.4.8 Development of Bioclusters to Boost India’s Biotechnology Sector
             10.4.9 Infrastructural Limitations in India, A Key Hindrance to Market Growth
             10.4.10 Biomedical Research in Australia
             10.4.11 Growth in Translational & Biomedical Research in Singapore
             10.4.12 Increase in Animal Research in Malaysia
             10.4.13 Rising Pharmaceutical & Biotechnology R&D Activities in South Korea
     10.5 Rest of the World
             10.5.1 Brazil: Growth in the Pharmaceutical, Biotechnology, and Research Industries
             10.5.2 Favorable Business Environment for the Pharmaceutical & Biotechnology Industries in Saudi Arabia & the UAE
             10.5.3 Increasing Investments in Mexico

11 Competitive Landscape (Page No. - 136)
     11.1 Overview
     11.2 Market Share Analysis
             11.2.1 Introduction
             11.2.2 Cell-Based Humanized Mouse Model Market
                        11.2.2.1 The Jackson Laboratory (US)
                        11.2.2.2 Taconic Biosciences (US)
             11.2.3 Genetic Humanized Mouse Model Market
                        11.2.3.1 Horizon Discovery Group (UK)
                        11.2.3.2 Taconic Biosciences (US)
     11.3 Competitive Scenario
             11.3.1 Agreements, Partnerships, and Collaborations
             11.3.2 Grants/Funds
             11.3.3 Product Launches
             11.3.4 Acquisitions
             11.3.5 Expansions
             11.3.6 Other Strategies

12 Company Profiles (Page No. - 145)
(Overview, Strength of Product Portfolio, Business Strategy Excellence, Products Offering, and Recent Developments)*
     12.1 The Jackson Laboratory
     12.2 Taconic Biosciences
     12.3 Crown Bioscience (Subsidiary of Jsr Corporation)
     12.4 Champions Oncology
     12.5 Horizon Discovery (Sage Labs)
     12.6 Hera Biolabs
     12.7 Genoway
     12.8 Vitalstar Biotechnology
     12.9 Ingenious Targeting Laboratory
     12.10 Axenis
     12.11 Trans Genic
     12.12 Harbour Antibodies (A Subsidiary of Harbour Biomed)
     12.13 Charles River Laboratories

*Details on Overview, Strength of Product Portfolio, Business Strategy Excellence, Products Offering, and Recent Developments Might Not Be Captured in Case of Unlisted Companies.

13 Appendix (Page No. - 180)
     13.1 Discussion Guide
     13.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
     13.3 Introducing RT: Real-Time Market Intelligence
     13.4 Available Customizations
     13.5 Related Reports
     13.6 Author Details


List of Tables (94 Tables)

Table 1 Sampling Frame: Primary Research
Table 2 Indicative List of Clinical Trails Conducted on Humanized Mice Models
Table 3 Indicative List of Research Studies Conducted on Humanized Mice Models
Table 4 Rat Model Models Market, By Type, 2015–2022 (USD Million)
Table 5 Genetic Humanized Mouse Models Market, By Region, 2015–2022 (USD Million)
Table 6 North America: Genetic Rat Model Market, By Country, 2015–2022 (USD Million)
Table 7 Europe: Genetic Rat Model Market, By Region, 2015–2022 (USD Million)
Table 8 Cell-Based Rat Model Market, By Type, 2015–2022 (USD Million)
Table 9 Cell-Based Rat Model Market, By Region, 2015–2022 (USD Million)
Table 10 North America: Cell-Based Market, By Country, 2015–2022 (USD Million)
Table 11 Europe: Cell-Based Rat Model Market, By Region, 2015–2022 (USD Million)
Table 12 CD34 Rat Model Market, By Region, 2015–2022 (USD Million)
Table 13 North America: CD34 Rat Model Market, By Country, 2015–2022 (USD Million)
Table 14 Europe: CD34 Humanized Mouse Models Market, By Region, 2015–2022 (USD Million)
Table 15 PBMC Rat Model Market, By Region, 2015–2022 (USD Million)
Table 16 North America: PBMC Rat Model Market, By Country, 2015–2022 (USD Million)
Table 17 Europe: PBMC Rat Model Market, By Region, 2015–2022 (USD Thousand)
Table 18 BLT Humanized Mouse Models Market, By Region, 2015–2022 (USD Thousand)
Table 19 North America: BLT Humanized Mouse Models Market, By Country, 2015–2022 (USD Thousand)
Table 20 Europe: BLT Rat Model Market, By Region, 2015–2022 (USD Thousand)
Table 21 Rat Model Market, By Application, 2015–2022 (USD Million)
Table 22 Indicative List of Recent Cancer Research Studies Using Humanized Mouse Models
Table 23 Rat Model Market for Oncology, By Region, 2015–2022 (USD Million)
Table 24 North America: Rat Model Market for Oncology, By Country, 2015–2022 (USD Million)
Table 25 Europe: Rat Model Market for Oncology, By Region, 2015–2022 (USD Million)
Table 26 Rat Model Market for Immunology and Infectious Diseases, By Region, 2015–2022 (USD Million)
Table 27 North America: Rat Model Market for Immunology and Infectious Diseases, By Country, 2015–2022 (USD Million)
Table 28 Europe: Rat Model Market for Immunology and Infectious Diseases, By Region, 2015–2022 (USD Million)
Table 29 Rat Model Market for Neuroscience, By Region, 2015–2022 (USD Million)
Table 30 North America: Rat Model Market for Neuroscience, By Country, 2015–2022 (USD Million)
Table 31 Europe: Rat Model Market for Neuroscience, By Region, 2015–2022 (USD Million)
Table 32 Rat Model Market for Toxicology, By Region, 2015–2022 (USD Million)
Table 33 North America: Rat Model Market for Toxicology, By Country, 2015–2022 (USD Million)
Table 34 Europe: Rat Model Market for Toxicology, By Region, 2015–2022 (USD Million)
Table 35 Rat Model Market for Hematopoiesis, By Region, 2015-2022 (USD Million)
Table 36 North America: Rat Model Market for Hematopoiesis, By Country, 2015–2022 (USD Million)
Table 37 Europe: Rat Model Market for Hematopoiesis, By Region, 2015–2022 (USD Million)
Table 38 Rat Model Market for Other Applications, By Region, 2015-2022 (USD Million)
Table 39 North America: Rat Model Market for Other Applications, By Country, 2015–2022 (USD Million)
Table 40 Europe: Rat Model Market for Other Applications, By Region, 2015–2022 (USD Million)
Table 41 Rat Model Market, By End User, 2015–2022 (USD Million)
Table 42 Rat Model Market for Pharmaceutical & Biotechnology Companies, By Region, 2015–2022 (USD Million)
Table 43 North America: Rat Model Market for Pharmaceutical & Biotechnology Companies, By Country, 2015–2022 (USD Million)
Table 44 Europe: Rat Model Market for Pharmaceutical & Biotechnology Companies, By Region, 2015–2022 (USD Million)
Table 45 Rat Model Market for Contract Research Organizations, By Region, 2015–2022 (USD Million)
Table 46 North America: Rat Model Market for Contract Research Organizations, By Country, 2015–2022 (USD Million)
Table 47 Europe: Market for Contract Research Organizations, By Region, 2015–2022 (USD Million)
Table 48 Market for Academic & Research Institutions, By Region, 2015–2022 (USD Million)
Table 49 North America: Market for Academic & Research Institutions, By Country, 2015–2022 (USD Million)
Table 50 Europe: Models Market for Academic & Research Institutions, By Country, 2015–2022 (USD Million)
Table 51 Market, By Region, 2015–2022 (USD Million)
Table 52 North America: Market, By Country, 2015–2022 (USD Million)
Table 53 North America: Rat Model Market, By Type, 2015–2022 (USD Million)
Table 54 North America: Cell-Based Humanized Mouse Models Market, By Type, 2015–2022 (USD Million)
Table 55 North America: Rat ModelMarket, By Application, 2015–2022 (USD Million)
Table 56 North America: Rat Model Market, By End User, 2015–2022 (USD Million)
Table 57 NIH Funding for Projects Related to Animal Models
Table 58 Recent Events Related to the Animal Models Market
Table 59 US: Market, By Type, 2015–2022 (USD Million)
Table 60 US: Cell-Based Rat Model Market, By Type, 2015–2022 (USD Million)
Table 61 US: Market, By Application, 2015–2022 (USD Million)
Table 62 US: Rat Model Market, By End User, 2015–2022 (USD Million)
Table 63 Canada: Market, By Type, 2015–2022 (USD Million)
Table 64 Canada: Cell-Based Rat Model Market, By Type, 2015–2022 (USD Thousand)
Table 65 Canada: Rat Model Market, By Application, 2015–2022 (USD Thousand)
Table 66 Canada: Humanized Mouse Models Market, By End User, 2015–2022 (USD Million)
Table 67 Europe: Rat Model Market, By Region, 2015–2022 (USD Million)
Table 68 Europe: Market, By Type, 2015–2022 (USD Million)
Table 69 Europe: Cell-Based Rat Model Market, By Type, 2015–2022 (USD Million)
Table 70 Europe: Market, By Application, 2015–2022 (USD Million)
Table 71 Europe: Rat Model Market, By End User, 2015–2022 (USD Million)
Table 72 EU5: Humanized Mouse Models Market, By Type, 2015–2022 (USD Million)
Table 73 EU5: Cell-Based Rat Model Market, By Type, 2015–2022 (USD Million)
Table 74 EU5: Market, By Application, 2015–2022 (USD Million)
Table 75 EU5: Rat Model Market, By End User, 2015–2022 (USD Million)
Table 76 RoE: Market, By Type, 2015–2022 (USD Million)
Table 77 RoE: Cell-Based Rat Model Market, By Type, 2015–2022 (USD Million)
Table 78 RoE: Market, By Application, 2015–2022 (USD Thousand)
Table 79 RoE: Rat Model Market, By End User, 2015–2022 (USD Million)
Table 80 Japan: Significant Partnerships
Table 81 Asia Pacific: Market, By Type, 2015–2022 (USD Million)
Table 82 Asia Pacific: Cell-Based Rat Model Market, By Type, 2015–2022 (USD Thousand)
Table 83 Asia Pacific: Market, By Application, 2015–2022 (USD Million)
Table 84 Asia Pacific: Rat Model Market, By End User, 2015–2022 (USD Million)
Table 85 RoW: Market, By Type, 2015–2022 (USD Million)
Table 86 RoW: Cell-Based Rat Model Market, By Type, 2015–2022 (USD Thousand)
Table 87 RoW: Market, By Application, 2015–2022 (USD Thousand)
Table 88 RoW: Rat Model Market, By End User, 2015–2022 (USD Thousand)
Table 89 Agreements, Partnerships, and Collaborations 2015–2018
Table 90 Grant/Fund, 2015–2018
Table 91 Product Launches, 2015–2018
Table 92 Acquisitions, 2015–2018
Table 93 Expansions, 2015–2018
Table 94 Other Strategies, 2015–2018


List of Figures (42 Figures)

Figure 1 Research Methodology: Global Humanized Mouse and Rat Models Market
Figure 2 Research Design: Global Humanized Mouse and Rat Models Market
Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Market Size Estimation Methodology: Bottom-Up Approach
Figure 5 Market Size Estimation Methodology: Top-Down Approach
Figure 6 Data Triangulation Methodology
Figure 7 Market, By Application (2017)
Figure 8 Rat Model Market, By Type, 2017 vs 2022
Figure 9 Cell-Based Humanized Mouse Models Market, By Type, 2017 vs 2022
Figure 10 Rat Model Market, By End User, 2017 vs 2022
Figure 11 Humanized Rat Models Market Overview
Figure 12 The Market in Asia Pacific to Witness the Highest Growth During the Forecast Period
Figure 13 Increasing Number of Research Activities Involving Humanized Mouse Models, A Major Factor Driving the Growth of the Market
Figure 14 Growing Demand for Personalized Medicine, A Major Factor Driving the Growth of the Humanized Rat Models Market
Figure 15 Pharmaceutical & Biotechnology Companies Accounted for the Largest Share of the Market in 2017
Figure 16 Genetic Humanized Mouse Models to Continue to Dominate the Humanized Mouse Models Market in 2022
Figure 17 Asia Pacific to Register the Highest CAGR During the Forecast Period
Figure 18 Drivers, Restraints, Opportunities, and Challenges
Figure 19 US: Clinical Trials Using Humanized Mice Models, By Indication (2013–2023)
Figure 20 US: Clinical Trials Using Humanized Mice Models, By Completion (2013–2023)
Figure 21 US: Clinical Trials Using Humanized Mice Models, By Phase (2013–2023)
Figure 22 US: Research Studies Using Humanized Mice Models, By Indication (2013–2023)
Figure 23 Genetic Humanized Mouse Models to Dominate the Market in 2017
Figure 24 CD34 Humanized Mouse Models Segment to Grow at the Highest CAGR During the Forecast Period
Figure 25 Humanized Rat Models Market, 2015–2022 (USD Million)
Figure 26 Oncology Segment Accounted for Largest Share of the Humanized Mouse Models Market in 2017
Figure 27 Pharmaceutical & Biotechnology Companies to Dominate the Humanized Mouse Models Market in 2017
Figure 28 North America Will Continue to Dominate the Humanized Mouse Models Market in 2022
Figure 29 North America: Market Snapshot
Figure 30 Europe: Market Snapshot
Figure 31 Cell Therapy Preclinical Studies in the UK, 2013–2016
Figure 32 Asia Pacific: Market Snapshot
Figure 33 RoW: Market Snapshot
Figure 34 Key Developments in the Humanized Mouse Model Market, 2015–2018
Figure 35 Market Share Analysis for Cell-Based Humanized Mouse Model, By Key Players, 2016
Figure 36 Market Share Analysis for Genetic Humanized Mouse Model, By Key Player, 2016
Figure 37 The Jackson Laboratory: Company Snapshot (2016)
Figure 38 Champions Oncology: Company Snapshot (2016)
Figure 39 Horizon Discovery: Company Snapshot (2016)
Figure 40 Genoway: Company Snapshot (2017)
Figure 41 Trans Genic: Company Snapshot (2016)
Figure 42 Charles River Laboratories: Company Snapshot (2016)


Request for detailed methodology, assumptions & how numbers were triangulated.

Please share your problem/objectives in greater details so that our analyst can verify if they can solve your problem(s).
3 2 8 8 2  
  • Select all
  • News-Letters with latest Market insights
  • Information & discussion on the relevant new products and services
  • Information & discussion on Market insights and Market information
  • Information & discussion on our events and conferences
    • Select all
    • Email Phone Professional and social network (Linkedin, etc)
COVID-19

Get in-depth analysis of the COVID-19 impact on the Humanized Mouse and Rat Model Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Humanized Mouse and Rat Model Market

Request For Special Pricing
Report Code
BT 4938
Published ON
Mar, 2018
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Humanized Mouse and Rat Model Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2020 MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

Home